As of 2024-12-14, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is (54.09) USD. This relative valuation is based on P/E multiples. With the latest stock price at 33.19 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -263.0%.
The range of the Relative Valuation is (55.41) - (57.02) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.6x - 40.2x | 34.4x |
| Forward P/E multiples | 19.0x - 28.4x | 19.4x |
| Fair Price | (55.41) - (57.02) | (54.09) |
| Upside | -267.0% - -271.8% | -263.0% |
| Date | P/E |
| 2024-12-13 | -16.51 |
| 2024-12-12 | -16.28 |
| 2024-12-11 | -16.91 |
| 2024-12-10 | -17.23 |
| 2024-12-09 | -17.42 |
| 2024-12-06 | -16.66 |
| 2024-12-05 | -16.64 |
| 2024-12-04 | -16.97 |
| 2024-12-03 | -17.22 |
| 2024-12-02 | -17.62 |
| 2024-11-29 | -16.88 |
| 2024-11-27 | -16.98 |
| 2024-11-26 | -16.23 |
| 2024-11-25 | -15.87 |
| 2024-11-22 | -15.30 |
| 2024-11-21 | -13.80 |
| 2024-11-20 | -13.67 |
| 2024-11-19 | -14.42 |
| 2024-11-18 | -13.02 |
| 2024-11-15 | -13.07 |
| 2024-11-14 | -13.96 |
| 2024-11-13 | -14.05 |
| 2024-11-12 | -14.55 |
| 2024-11-11 | -14.71 |
| 2024-11-08 | -14.91 |
| 2024-11-07 | -14.29 |
| 2024-11-06 | -14.34 |
| 2024-11-05 | -13.96 |
| 2024-11-04 | -14.20 |
| 2024-11-01 | -13.92 |
| 2024-10-31 | -13.56 |
| 2024-10-30 | -13.78 |
| 2024-10-29 | -13.63 |
| 2024-10-28 | -13.60 |
| 2024-10-25 | -13.27 |
| 2024-10-24 | -13.72 |
| 2024-10-23 | -13.42 |
| 2024-10-22 | -13.73 |
| 2024-10-21 | -13.37 |
| 2024-10-18 | -13.93 |
| 2024-10-17 | -13.89 |
| 2024-10-16 | -13.90 |
| 2024-10-15 | -13.90 |
| 2024-10-14 | -13.62 |
| 2024-10-11 | -13.50 |
| 2024-10-10 | -13.26 |
| 2024-10-09 | -13.38 |
| 2024-10-08 | -13.63 |
| 2024-10-07 | -13.65 |
| 2024-10-04 | -13.68 |